Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
deferasirox + deferiprone
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination iron chelation therapy consisting of two oral iron chelators, deferasirox and deferiprone. This combination is used primarily for treating transfusion-induced iron overload in patients with conditions like β-thalassemia major, particularly those with suboptimal response to monotherapy. Deferasirox is a tridentate iron chelator that binds iron in a 2:1 ratio and is excreted primarily through feces, while deferiprone is a bidentate chelator requiring three molecules to bind one iron ion and is excreted through urine. The combination has demonstrated superior efficacy in reducing serum ferritin levels and improving cardiac iron removal compared to monotherapy in several clinical studies.
- Other names
- deferiprone + deferasiroxDFP + DFXDFP + ICL670
Beyond the preview
Go deeper on deferasirox + deferiprone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on deferasirox + deferiprone.